Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-12-17
2011-10-11
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S561000, C514S563000, C562S512000
Reexamination Certificate
active
08034836
ABSTRACT:
An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine.
REFERENCES:
patent: 4379177 (1983-04-01), McCoy et al.
patent: 4743614 (1988-05-01), Terano et al.
Mostad et al., 1986, CAS: 104:197543.
Pradhan et al., Journal of Chemical and Engineering Data, 2000, 45(1):140-143.
Ramaswamy et al., J. Raman Spectrosc. 34:50-56 (2003).
Rajkumar and Ramakrishnan, J. Raman Spectrosc. 31:1107-1112 (2000).
Petrosyan et at, J. Molecular Structure 794:160-167 (2006).
Jablecka et al., Med Sci Monit 10(1):CR29-32 (2004).
Maynard et al., J. Nutr. 131:287-290 (2001).
Rytlewski et al., European Journal of Obstetrics & Gynecology and Reproductive Biology 138:23-28 (2008).
Schwedheim et al., Br J Clin Pharmacol 65(1):51-59 (2007).
Smith et al., J. Thorac Cardiovasc. Surg 132:58-65 (2006).
Rytlewski et al., Eur J. Clin Invest 35 (1):32-37 (2005).
Ming et al., Circulation 110:3708-3714 (2004).
Romero et al., Cardiovascular Drug Reviews 24(3-4):275-290 (2006).
Oka et al., Vasc Med 10:265-274 (2005).
Hayashi et al., PNAS 102(38):13681-13686 (2005).
Grasemann et al., Eur Respir J 25:62-68 (2005).
Boger, J. Nutr 137:1650S-1655S (2007).
Beghetti et al., J. Thorac Cardiovasc. Surg 132(6):1501-1502 (2006).
Berge, Journal of Pharmaceutical Sciences, Jan. 1977, vol. 66, No. 1.
Takahashi et al., “Characterization of the influence of nitric oxide donors on intestinal absorption of macromolecules,” International Journal of Pharmaceutics vol. 286:89-97 (2004).
Fetih et al., “Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu 1,7]-eel calcitonin in rats,” Journal of Controlled Release vol. 106:287-297 (2005).
Fetih et al., “Excellent Absorption Enhancing Characteristics of NO Donors for Improving the Intestinal Absorption of Poorly Absorbable Compound Compared with Conventional Absorption Enhancers,” Drug Metab. Pharmacokinet. vol. 21(3):222-229 (2006).
Aniya et al. , “Evaluation of Nitric Oxide Formation from Nitrates in Pig Coronary Arteries,” Jpn. J. Pharmacal. vol. 71: 101-107 (1996).
T.F. Luscher, “Endogenous and exogenous nitrates and their role in myocardial ischaemia,” Br. J. Clin. Pharmacol. vol. 34:29S-35S (1992).
Shiraki et al., “The hypotensive mechanisms of the new anti-anginal drug, N-(2-Hydroxyethyl) Nicotinamide Nitrate (SG-75) in beagle dogs,” Japan. J. Pharmacol. vol. 31:921-929 (1981).
CFIndustries, “Material Safety Data Sheet for Urea Ammonium Nitrate Solution (UAN),” available at www.cfindustries.com/pdf/UANMSDS.pdf Oct. 25, 2006.
Slart et al., “Nitrate Administration Increases Blood Flow in Dysfunctional but Viable Myocardium, Leading to Improved Assessment of Myocardial Viability: A PET Study,” J. Nucl. Med. vol. 47: 1307-1311 (2006).
Fayers et al., “Nitrate tolerance and the links with endothelial dysfunction and oxidative stress,” Blackwell Publishing Ltd Br. J. Clin. Pharmacol. vol. 56:620-628 (2003).
Harm J. Knot. “Nitrate Tolerance in Hypertension New Insight Into a Century-Old Problem,” Circulation Research vol. 93:799-801 (2003).
Schulz et al., “Functional and Biochemical Analysis of Endothelial (Dys)function and NO/cGMP Signaling in Human Blood Vessels With and Without Nitroglycerin Pretreatment,” Circulation Research vol. 105:1170-1175 (2002).
Hatanaka et al., “Stereoselective Pharmacokinetics and Pharmacodynamics of Organic Nitrates in Rats,” J Pharmacol Exp Ther. vol. 298(1):346-53 (2001).
Chabot et al., “Characterization of the vasodilator properties of peroxynitrite on rat pulmonary artery: role of poly (adenosine 5′-diphosphoribose) synthase,” British Journal of Pharmacology vol. 121:485-490 (1997).
Bauer et al., “Vascular and Hemodynamic Differences between Organic Nitrates and Nitrites,” The Journal of Pharmacology and Experimental Therapeutics JPET vol. 280:326-331 (1997).
Niu et al., Eur J. Pharmacol 580:169-174 (2008).
Tan et al., Vasc Pharmacol 46:338-345 (2007).
Ahtee et al., J. Nutr 116:2555-2556 (1986).
Larsen et al., B. Acta Physiol 191(1):59-66 (2007).
Bloomer et al., J Int Soc Sports Nutr 4(22):1-6 (2007).
Kramer Ronald
Nikolaidis Alexander
Booth Udall, PLC
Shiao Rei-tsang
ThermoLife International, LLC
LandOfFree
Amino acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272734